ClinicalTrials.gg
CompletedNCT05164133Updated Apr 29, 2024

A Study Evaluating Tocilizumab in Pediatric Patients Hospitalized With COVID-19

A Phase 1 interventional study of Tocilizumab in COVID-19, sponsored by Hoffmann-La Roche. Completed at 25 sites in 11 countries. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2024-04-29.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2024, 2 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
2
Allocation
Not applicable
Ages
Up to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies testing tocilizumab in COVID-19 — 3 open to participants now, 4 under way, 2 of them phase 3. tocilizumab · COVID-19.

Enrollment
36th of 38
2 · median 150
Started
2022
the only one that year
Phase 1
3 of 38
1 open now
Registered
36th of 38
by date
Lead sponsor
4 of 38
Hoffmann-La Roche

Among the 38 studies testing tocilizumab in COVID-19, this one is the 36th largest by enrollment, is the only one that started in 2022, is one of 3 in phase 1, and was the 36th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

3 of the 38 studies testing tocilizumab in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: Up to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing tocilizumab in COVID-19, or all of them as a file.
02

Study summary

This is a single-arm, open-label study to assess the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of tocilizumab (TCZ) for the treatment of pediatric patients from birth to less than 18 years old hospitalized with COVID-19 and who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.

03

Conditions studied

  • COVID-19

Browse trials for

04

Who can participate

Ages eligible
Up to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hospitalized with COVID-19 confirmed per a positive PCR of any specimen (e.g., respiratory, blood, urine, stool, or other bodily fluid) and evidenced by chest x-ray or CT scan
  • Receiving systemic at baseline
  • Oxygen saturation \< 93% on room air, or requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) to maintain oxygen saturation > 92% at screening and baseline

Exclusion criteria

Exclusion Criteria:

  • Gestational age \< 37 weeks
  • Known severe allergic reactions to TCZ or other monoclonal antibodies
  • Active tuberculosis infection
  • Uncontrolled active bacterial, fungal, viral, or other infection (besides COVID-19)
  • Diagnosis or suspected diagnosis of multisystem inflammatory syndrome in children (MIS-C)
  • In the opinion of the investigator, progression to death is imminent and inevitable within the next 48 hours, irrespective of the provision of treatments
  • Have received oral anti-rejection or immunomodulatory drugs (including TCZ) within the past 3 months prior to enrollment
  • Treatment with an drug within 5 drug-elimination half-lives or 30 days, whichever is longer, of enrollment (except for anti-SARS-CoV-2 antibodies or directly-acting antivirals)
  • Participating in another interventional drug clinical trial (except for anti-SARS-CoV-2 antibodies or directly-acting antivirals)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    All Participants

    Participants who are hospitalized with COVID-19 and who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation will receive a single dose of TCZ on Day 1, with the option to receive a second dose 8-24 hours later if clinically indicated.

    Drug: Tocilizumab

Interventions

  • Participants will receive intravenous (IV) tocilizumab

06

What researchers measure

Primary outcomes

  1. Serum concentration of TCZ

    Time frame: Through Day 28

  2. Maximum serum concentration (Cmax) of TCZ

    Time frame: Through Day 28

  3. Area under the curve from Days 0-28 (AUC days 0-28) of TCZ

    Time frame: Days 0-28

  4. Serum concentration on Day 28 (C day 28) of TCZ

    Time frame: Day 28

  5. Clearance (CL) of TCZ

    Time frame: Through Day 28

  6. Volume of distribution of TCZ

    Time frame: Through Day 28

Secondary outcomes

  1. Duration of 90% saturation of sIL-6R

    Time frame: Through Day 28

  2. Concentration of IL-6

    Time frame: Through Day 60

  3. Concentration of sIL-6R

    Time frame: Through Day 60

  4. Concentration of C-reactive protein (CRP)

    Time frame: Through Day 60

  5. Percentage of participants with adverse events

    Time frame: Up to 60 days

  6. Percentage of participants with severe adverse events

    Time frame: Up to 60 days

07

Study locations

25 sites
  • Reagan UCLA Medical Center
    Los Angeles, California 90095, United States
  • The University of Chicago
    Chicago, Illinois 60637, United States
  • Central Michigan University College of Medicine
    Mount Pleasant, Michigan 48858-3803, United States
  • Feinstein Institute for Medical Research
    Manhasset, New York 11030, United States
  • University Hospitals Cleveland Medical Center, Rainbow Babies and Childrens Hospital
    Cleveland, Ohio 44106-2624, United States
  • UT Physicians - Pediatric Center - Texas Medical Center
    Houston, Texas 77030-3005, United States
  • University of Utah - PPDS
    Salt Lake City, Utah 84108-1287, United States
  • Santa Casa de Misericordia de Porto Alegre
    Porto Alegre, RS 90020-090, Brazil
  • Klinika Za Djecje Bolesti Zagreb
    Zagreb, 10000, Croatia
  • University Hospital for Infection Diseases "Dr. Fran Mihaljevic" - PPDS
    Zagreb, 10000, Croatia
  • CHRU Montpellier; SMPEA Peyre Plantade Centre de Ressources Autisme
    Montpellier, 34295, France
  • Hospital Necker
    Paris, 75015, France
  • Assistance Publique Hopitaux de Paris
    Val-de-Marne, 94275, France
  • Uniklinik Köln
    Köln, 50937, Germany
  • Universitätsklinikum Ulm
    Ulm, 89081, Germany
  • Hippokration Hospital
    Thessaloniki, 546 42, Greece
  • IRCCS Ospedale Pediatrico Bambino Gesù - INCIPIT - PIN
    Roma, Lazio 00165, Italy
  • ASST di Lecco - Presidio Ospedaliero A. Manzoni di Lecco
    Lecco, Lombardia 23900, Italy
  • Szpital Kliniczny im Karola Jonschera Uniwersytetu Medycznego im Karola Marcinkowskiego w Poznaniu
    Poznan, 60-572, Poland
  • Global Clinical Trials Sunnyside
    Pretoria, 0001, South Africa
  • Hospital Sant Joan de Deu - PIN; Unitat de Recerca - Farmacia
    Esplugues de Llobregat, Barcelona 08950, Spain
  • Hospital Infantil Universitario Niño Jesus; Sección de Neuropediatria
    Madrid, 28009, Spain
  • Hospital Universitario 12 De Octubre
    Madrid, 28041, Spain
  • Hospital Universitario La Paz - PPDS
    Madrid, 28046, Spain
  • Great North Childrens Hospital
    Newcastle upon Tyne, NE1 4LP, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Mar 2024, 21 months.

Of 233 industry-sponsored phase 1 interventional studies under COVID-19, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 12. This study's 21 months is above that.

Counting every sponsor, half of 384 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2021
First posted
Dec 20, 2021
StartActual
Jun 10, 2022
Primary completionActual
Mar 27, 2024
CompletionActual
Mar 27, 2024
Last update
Apr 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05164133
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 20, 2021
Start date
Jun 10, 2022
Primary completion
Mar 27, 2024
Completion
Mar 27, 2024
Last update
Apr 29, 2024

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion